The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma
- 2 September 2022
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 45 (1) , 13-19
Abstract
Introduction: In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie‐Salmon classification and the international staging system (ISS) that takes the serum ß2 microglobulin and albumin levels, platelet‐to‐lymphocyte ratio (PLR), neutrophil‐to‐lymphocyte ratio (NLR), and monocyte‐to‐lymphocyte ratio (MLR). This study investigates the effect of haemoglobin, albumin, lymphocyte and platelet (HALP) score which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with multiple myeloma on prognosis.Methods: A total of 200 multiple myeloma patients with HALP scores calculated from serum haemoglobin, albumin, lymphocyte count and platelet levels at the time of diagnosis were retrospectively examined. The effect of HALP score on overall survival (OS) and progression‐free survival and its relationship between the previously evaluated prognostic parameters were investigated.Results: The optimal cut‐off value with the ROC curves for the HALP score was 28.8. The patients were divided into two groups according to the optimal value of the HALP score (low‐score group: HALP ≤28.8 [n: 134] and high‐score group HALP >28.8 [n: 66]). In the group with the high HALP score, the OS was statistically longer than the low HALP score group (84 months and 53 months; p = 0.0001). In addition, when the effects of NLR, PLR, HALP score and ISS stage on OS were examined by multivariate analysis, all these markers were found to be statistically significant predictors.Conclusions: HALP score may be a valuable prognostic marker for patients with multiple myeloma.Keywords
This publication has 34 references indexed in Scilit:
- Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance statusInternational Journal of Clinical Oncology, 2013
- Prognostic Value of Neutrophil-to-lymphocyte Ratio and Establishment of Novel Preoperative Risk Stratification Model in Bladder Cancer Patients Treated With Radical CystectomyUrology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaLeukemia, 2010
- Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancerBiomarkers, 2010
- The Diversity of Nutritional Status in Cancer: New InsightsThe Oncologist, 2010
- Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor modelJournal of Clinical Investigation, 2010
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal of Cancer, 2009
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinomaHPB, 2007